Contacts: Steve Parkinson President and CEO TranXenoGen, Inc. (508) 842 5036 Email: Sparkinson@TranXenoGen.com Michael Padley/Nicholas Nelson College Hill Associates Tel: 020 7457 2020 TranXenoGen Licences Novel Anti-Cancer Protein Shrewsbury, MA, March 2, 2001 - TranXenoGen, Inc. ("TranXenoGen") the AIM listed avian transgenic protein drug manufacturing company based in Shrewsbury, Massachusetts, announces that it has licensed, on a worldwide exclusive basis, a novel anti-cancer product, human anti-neoplastic urinary protein ("ANUP"), from the Memphis, Tennessee biotechnology company, Antitumor Research Products, Inc. ("ARP"). ANUP, originally derived from human urine, is believed to be a protein produced by normal healthy humans as an anti-cancer surveillance protein. From circulation in the blood, ANUP is excreted from the body into the urine. ARP has shown in animal studies using nude mice that ANUP inhibits the growth of various human tumor cell lines including Karposi’s sarcoma, cervical and laryngeal tumors. In vitro, ANUP has proven to be remarkably effective against a wide variety of tumor cell lines while having no effect on normal human cells, suggesting that ANUP may prove to be a broad-spectrum anti-cancer agent. Commenting on the agreement, Dr. Sloane, President of ARP, with over fifty years of research experience in both industry and academia, said: "I am delighted to be working with TranXenoGen to take ANUP forward into clinical trials. My first wife died tragically of cancer many years ago and since then it has been my life’s work to develop an effective treatment for this disease which is still the number one killer in the world." Steve Parkinson, President and CEO of TranXenoGen, said: "We were excited when first presented with the data on ANUP. This product fits well with our low cost, high volume manufacturing technology in chickens as it will be required in large quantities." "This is a very significant step for TranXenoGen. In addition to our generic biological products, our portfolio now includes a novel therapeutic product that we believe further enhances the value of the Company's product pipeline. TranXenoGen has licensed an issued patent for the use of ANUP as an anti-cancer agent, as well as additional patent filings as part of the agreement, financial terms of which were not disclosed. TranXenoGen intends to conduct additional animal studies with ANUP this year while developing its manufacturing capabilities and clinical plan for the product. TranXenoGen, Inc. (symbol: TXN.L) is a publicly listed company on the Alternative Investment Market of the London Stock Exchange. The company specialises in the application of second-generation avian transgenic technology to the production of complex high-volume human therapeutic proteins in the albumin fraction of transgenic chicken’s eggs.